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Abstract
Background: Major Clostridium difficile virulence factors are the exotoxins TcdA and TcdB. Due
to the large size and poor stability of the proteins, the active recombinant TcdA and TcdB have
been difficult to produce.
Results: The toxin genes tcdA and tcdB were amplified by PCR using chromosomal DNA from a
toxigenic strain as a template, and cloned into a shuttle vector pHis1522. The sequences of both
tcdA and tcdB genes in the vector have been verified by DNA sequencing. The constructs were
transformed into B. megaterium protoplasts and the protein expression was controlled under a
xylose promoter. The recombinant toxins (rTcdA and rTcdB) were purified from bacterial crude
extracts. Approximately 5 – 10 mg of highly purified recombinant toxins were obtained from one
liter of bacterial culture. The resulting rTcdA and rTcdB had similar molecular masses to the native
toxins, and their biological activities were found to be similar to their native counterparts after an
extensive examination.
Conclusion: We have generated the full length and active recombinant TcdA and TcdB in Bacillus
megaterium.
Background
Clostridium difficile is a Gram-positive, spore-forming
anaerobic bacillus. It is the most common cause of noso-
comial antibiotic-associated diarrhea and the etiologic
agent of pseudomembranous colitis [1]. Antibiotic usage
results in a reduction of commensal microflora in the gut,
which permits C. difficile to proliferate more extensively,
leading to the production of toxins [2]. C. difficile associ-
ated diarrhea (CDAD) include a range of symptoms vary-
ing from mild diarrhea to severe fulminate lethal disease
[3]. Recent outbreaks of highly virulent C. difficile strains
[4,5] have increased the urgency to devote greater
resources towards the understanding of the molecular,
genetic, and biochemical basis for the pathogenesis, with
a view to use such information to develop novel prevent-
ative and treatment modalities.
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Two exotoxins produced by toxigenic C. difficile, toxin A
(TcdA) and toxin B (TcdB), are most extensively studied
and thought to be major virulent factors of CDAD [6,7].
TcdA (308 kDa) and TcdB (269 kDa) belong to the large
clostridial cytotoxin (LCT) family and share 49% amino
acid identity [8]. The two toxins have a similar structure
containing a putative receptor binding domain (RBD), a
transmembrane domain (TMD), and a glucosyltransferase
domain [8,9]. After receptor-mediated internalization and
intracellular cleavage, the toxins glucosylate members of
the Rho-Rac family of small GTPases at a specific threo-
nine residue in host intestinal epithelial cells, leading to
alterations in the actin cytoskeleton, massive fluid secre-
tion, acute inflammation, and necrosis of the colonic
mucosa [7]. Purified TcdA possesses potent enterotoxic
and pro-inflammatory activity, as determined in ligated
intestinal loop studies in animals [10,11]. TcdA is also
cytotoxic to cultured cells in a picomolar to nanomolar
range. TcdB, more cytotoxic to cultured cells than TcdA,
was previously reported to exhibit no enterotoxic activity
in animals [11,12], but recent studies have found entero-
toxic and proinflammatory activities in human intestinal
xenografts in severe combined immunodeficient (SCID)
mice [13]. Furthermore, the TcdA-B+ C. difficile strains are
responsible for pseudomembranous colitis in some
patients [14,15].
It is desirable to obtain relatively pure and biologically
active TcdA and TcdB for studying the pathogenesis of
CDAD and host immune response to the infection and for
generating immunological tools for research and clinical
diagnosis. The native toxins are usually purified from tox-
igenic C. difficile culture supernatant, which involves mul-
tiple steps and the purity is often unsatisfactory [16-18].
Attempts have been made to clone and express C. difficile
toxins in Escherichia coli [19-21], but it is unclear whether
or not purified toxins were obtained from the bacterial
lysate in these studies. The Gram-positive Bacillus megate-
rium expression system may offer an alternative for the
expression of C. difficile toxins due to several advantages
over the E. coli system, including the lack of alkaline pro-
teases activity and endotoxin LPS, capable of secreting
expressed heterologous protein into the medium [22,23].
Although the expression level was low, Burger et al [24]
were the first to successfully express and obtain the puri-
fied recombinant TcdA in B. megaterium. In this study, we
have expressed the full-length of both TcdA and TcdB in B.
megaterium. We were able to obtain an average of 5 – 10
mg of highly purified recombinant proteins from one liter
of total bacterial culture. Both recombinant TcdA and
TcdB were biologically active similar to their native puri-
fied toxins.
Results
Cloning and expression of the recombinant toxins
After enzyme (BsrGI/KpnI) digestion of pHis1522 vector
and PCR products, the ligation was set up and the mixture
was incubated at 4°C for 2 days. The transformation was
carried out following the standard protocol and more
than 90 bacterial colonies were picked up. The plasmids
(named pHis-TcdB) from these colonies were subjected to
screening by digestion with a variety of enzymes. pHis-
TcdB from multiple clones was used to transform B. meg-
aterium protoplasts, and tetracycline-resistant clones were
picked up. After induction with xylose, the bacterial crude
extracts from approximately 30 different transformed
clones were subjected to screening for activity causing
rounding of cultured cells. The clones with high activities
were selected and a Coomassie-staining gel showed
expression of a protein of about 270 kDa when xylose was
added for induction (Figure 1A Lane1). This protein was
purified by Ni-affinity column from a total crude extract,
resulting in a major band with molecular weight about
270 kDa and some weak contaminant bands of lower
molecular weights (Figure 1A). A further step of ion-
exchange purification resulted in a highly pure 270 kDa-
protein without any visible contaminant bands on
Coomassie-stained gels (Figure 1B). Western blot analysis
using specific antibodies against His-tags (data not
shown) and toxin B (Figure 1C) identified the 270 kDa
protein from B. megaterium lysate as the recombinant His-
tagged toxin B (rTcdB). From one liter of bacterial culture,
approximately 10 mg of rTcdB was obtained. The pHis-
TcdB used to transform the B. megaterium was subjected to
DNA sequencing for the verification of tcdB gene, and no
mutation was found (data not shown).
B. megaterium has a secretory pathway [22,23], which
transports the expressed heterologous proteins into the
medium. Because the native toxins are secreted into
medium by toxigenic C. difficile, we attempted the expres-
sion of rTcdB in a secretory form. The DNA sequence
encoding a 28-amino-acid signal peptide derived from B.
megaterium  extracellular esterase LipA [22] was synthe-
sized and inserted at the 5' of tcdB. The resulting pHis-SP-
TcdB was transformed into B. megaterium. Figure 1D
shows the presence of a 270 kDa band from the concen-
trated bacterial culture supernatant on a Coomassie
stained SDS-PAGE gel (lane 2). Western blot and cytotox-
icity assays confirmed the expression of the secretory form
of rTcdB. The expression level of this secretory form was,
however, very low and we were unable to obtain a suffi-
cient amount of purified rTcdB from the supernatant.
A similar strategy was utilized to clone and express recom-
binant TcdA. On a Coomassie stained SDS-PAGE gel of
total bacterial lysate, a clear protein band of 308 kDa
appeared only upon induction with xylose in pHis-TcdA-BMC Microbiology 2008, 8:192 http://www.biomedcentral.com/1471-2180/8/192
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transformed B. megaterium (Figure 2A). His-tag combined
with thyroglobulin affinity purifications resulted in a sin-
gle strong band (Figure 2A Lane 5), which was confirmed
to be TcdA by western blot analysis (Figure 2B). The pHis-
TcdA used to transform the B. megaterium was subjected to
DNA sequencing for the verification of tcdA gene, and no
mutation was found (data not shown).
Cytopathic effect of recombinant toxins
We compared the cytopathic effects of recombinant and
native toxins on cultured human epithelial HT-29 (data
not shown) and mouse intestinal epithelial CT26 cells
(Figure 3). rTcdA (Figure 3I and 3K) at 20 or 200 ng/ml
caused CT26 cell rounding similarly to native TcdA (Fig-
ure 3J and 3L). Both rTcdB and native TcdB were more
potent, capable of causing cell rounding at a much lower
concentration than those of rTcdA or native TcdA (Figure
3E, F, G, and 3H). After xylose induction, both superna-
tant (Figure 3D) and total cell lysate (data not shown)
from pHis-SP-TcdB transformed B. megaterium caused cell
rounding, whereas the bacterial culture supernatants from
pHis-TcdB transformed B. megaterium with (Figure 3C) or
without (Figure 3B) xylose induction did not cause cell
rounding. The same concentration of xylose in BHI
medium did not cause any cell rounding (data not
shown), suggesting the effects were specifically caused by
the secreted toxin. Furthermore, the cytopathic effects of
both rTcdA and native TcdA were blocked completely by a
rabbit polyclonal antibody against TcdA (Figure 3M and
3N).
Cytotoxic effect of recombinant toxins
It has been demonstrated that both TcdA and TcdB induce
intestinal epithelial cells to undergo apoptosis [25-27].
We next compared the cytotoxicity of recombinant toxins
to their native counterparts on cultured epithelial cells. As
shown in Figure 4A, both native and recombinant TcdA
induced a comparable and dose-dependent cell death of
CT26 cells. Similarly, the exposure of CT26 cells to rTcdB
induced a comparable cell death with nTcdB as deter-
mined by MTT assay (Figure 4B). These data indicate that
the recombinant TcdA and TcdB have similar cytotoxic
activity to their native counterparts in CT26 cells.
Glucosylation of Rac1 by recombinant toxins
C. difficile TcdA and TcdB target host cell Rho GTPase by
glucosylating these proteins at the specific Thr37 (Rho A)
or Thr35 (CDC42 and Rac1) residues [28,29]. To deter-
mine whether recombinant toxins can glucosylate Rac1
protein of host cells, mouse intestinal epithelial CT26
cells were treated with recombinant or native TcdA and
TcdB for 5 hr. Western blot showed that both rTcdA and
nTcdA treatment induced a dose-dependent, reduced rec-
ognition of Rac1 by monoclonal antibody (anti-Rac1
clone 102) that recognizes non-glucosylated Rac1 [30]
(Figure 5A). The reduced recognition of Rac1 was not the
results of protein degradation, because total Rac1 protein
remained unchanged as determined by western blot with
an antibody (clone 23A8) recognizing both glucosylated
and unmodified Rac1 (data not shown). Both rTcdA and
nTcdA at 40 ng/ml resulted in a complete glucosylation of
Rac1 whereas 8 or 1.6 ng/ml of TcdA led to a partial gluc-
osylation. rTcdB or nTcdB exposure resulted in a com-
pletely glucosylation of Rac1 at a dose range from 0.4 – 2
ng/ml (Figure 5B), indicating that the glucosyltransferase
activity of TcdB was more potent than TcdA. These results
were consistent with the activity of native C. difficile toxins
in which TcdB is more toxic to cultured cells than TcdA.
The treatment of rTcdA and rTcdB also led to the gluco-
sylation of Rac1 in RAW 264.7 and CHO cells (data not
shown).
Both TcdA and TcdB are thought to bind to specific cellu-
lar receptor(s), which mediate their cellular uptake
through endocytosis [31-33]. Lysosomotropic agents such
as chloroquine and NH4Cl can inhibit toxin-mediated
cytotoxicity, suggesting that the endosomal acidification
is involved in toxin intracellular trafficking [34,35]. To
determine whether or not the cellular activity of the
recombinant toxins also require endosomal acidification,
CT26 cells were pre-incubated with NH4Cl for 30 min
before the toxin exposure. While the exposure of CT26
cells to rTcdA or rTcdB induced the glucosylation of Rac1,
pretreatment of cells with ammonium chloride com-
pletely blocked such an activity (Figure 5C).
Disruption of tight junctions of intestinal epithelial cells by 
recombinant toxins
It is known that TcdA and TcdB alter the structure of intes-
tinal epithelia by disrupting tight junctions [36]. We
investigated whether or not the recombinant toxins we
generated have similar activities. Human intestinal epi-
thelial HCT-8 cells were cultured in a transwell for 10 to
14 days until transepithelial resistance (TER) reached
1000 Ω*cm2 and tight junctions were formed (Figure 6A).
rTcdA did not alter cell-cell connections of HCT-8 cells
within 4 hr of treatment (Figure 6B and 6C) but disrupted
tight junctions after 6 hr of treatment (Figure 6D). rTcdB,
at the same concentration with rTcdA, completely dis-
rupted the tight junctions of HCT-8 within 2 hr of treat-
ment (Figure 6E and 6F).
Discussion
CDAD is largely attributed to the bacterial exotoxins TcdA
and TcdB, although other virulence factors probably also
play some roles [7]. Both toxins glucosylate Rho GTPase
family proteins, leading to their inactivation [1,7]. To
study the pathogenesis of CDAD and host immune
response to the toxins, and to use the toxins as a research
tool for signal transduction involving Rho GTPases, it isBMC Microbiology 2008, 8:192 http://www.biomedcentral.com/1471-2180/8/192
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Expression and purification of recombinant TcdB Figure 1
Expression and purification of recombinant TcdB. pHis-TcdB plasmid was transformed to B. megaterium protoplasts. 
Several transformed colonies were picked up and the expression of rTcdB was induced by xylose. (A) His-tag affinity purifica-
tion of total lysate from B. megaterium. Lane 1: total bacterial lysate; Lane2: flow-through; Lane 3: wash; lane 4–6: elution frac-
tion 1–3. (B) Anion-exchanging column fractionation after Ni-affinity chromatography. nTcdB: purified native TcdB from C. 
difficile culture supernatant. Lane 1: Elution fraction 2 from (A); Lane 2–8: fractions from a gradient salt elution. Fraction 5 and 
6 contain purified rTcdB. (C) Western blot results of purified native TcdB and rTcdB of combined fraction 5 and 6 from (B). 
(D) Coomassie staining of SDS-PAGE from total sonication lysates a pHis-TcdB transformed clone (lane 1), concentrated 
supernatant from pHis-SP-TcdB transformed clone (lane 2) and purified native TcdB (lane 3). M indicates molecular weight 
marker and 250 kDa is showed.
250
M AB 1  2  3   4  5  6 1   2   3   4   5   6  7  8 M
nTcdB rTcdB
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necessary to obtain large quantities of highly purified
active TcdA and TcdB. Native toxins can be purified from
toxigenic C. difficile culture supernatant. The purification
process however usually involves multiple steps such as
ultrafiltration, ammonium sulfate precipitation, and ion-
exchange chromatography [17,18]. In the case of TcdA,
affinity purification through thyroglobulin is available
and relatively pure TcdA can be obtained ([16] and
unpublished data). TcdB however is often contaminated
with some unknown substance even after extensive purifi-
cation steps ([18] and unpublished data). Gene engineer-
ing to generate recombinant toxins seems to be a logical
approach for obtaining large quantities of pure toxin pro-
teins. The E. coli system is popular and is widely used for
the expression of recombinant proteins. Several studies
have reported to have cloned and expressed active C. diff-
icile toxins in E. coli, but failed to demonstrate that the
purified toxins were obtained from bacterial extracts [19-
21]. Burger et al was the first to report a successful expres-
sion of recombinant TcdA using Bacillus megaterium sys-
tem [24]. Recombinant TcdB, however, has not yet been
stably expressed. In this study, we were successfully
Expression and purification of recombinant TcdA Figure 2
Expression and purification of recombinant TcdA. pHis-TcdA plasmid was transformed into B. megaterium protoplasts. 
Over 20 transformed colonies were picked up and the expression of rTcdA was induced by xylose. (A) Coomassie staining of 
SDS-PAGE from crude bacterial extracts: Lane 1 shows no xylose induction; Lane 2 to 4 shows three different clones with 
xylose induction; Lane 5 shows purified rTcdA after Ni-affinity and thyroglobulin chromatograph. M shows molecular weight 
marker and the top band indicates 250 kDa. (B) Western blot results of the purified native TcdA (lane 1) and rTcdA (lane 2).
M  1   2  3  4    5 A B rTcdA
TcdABMC Microbiology 2008, 8:192 http://www.biomedcentral.com/1471-2180/8/192
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expressing a full-length recombinant TcdB in B. megate-
rium and greatly enhanced the expression level of recom-
binant TcdA.
Because E. coli expression system is widely used and easy-
to-handle, we have utilized various E. coli expression vec-
tor systems to clone and express both toxins and found
that both recombinant TcdA and TcdB were expressed in
E. coli but we were unable to obtain the purified toxins
from the bacterial lysate (unpublished data). The large
size of the heterologous proteins may possibly be prone to
protease digestion, and intrinsic protease activities of
these toxins [37,38] may also contribute to the instability.
Another possible reason for the inability to obtain puri-
fied recombinant toxins from E. coli is that the expression
level was too low. In fact, large proteins are difficult to
express at high levels in E. coli. Furthermore, an unusually
high content of AT (~70%) in these clostridial gene
sequences and a different codon -usage make them partic-
ularly difficult to express at a high level in E. coli [39,40].
There are several advantages associated with B. megaterium
expression system including lack of alkaline phosphatase
and endotoxin LPS. More importantly, B. megaterium has
been successfully used to express rTcdA [24], we therefore
decided to use this system. Initially, we followed the
reported cloning strategy but we were unsuccessful. This
might be due to the extremely low ligation efficiency [24]
when putting several fragments together during the clon-
ing. We then changed our strategy to a direct PCR ampli-
fication of whole toxin genes. However, this strategy was
associated with a potential risk that PCR might introduce
mutations due to the large size of the genes (7101 bp and
8133 bp for tcdB and tcdA respectively). Because of the
large size of both genes, it was impossible to sequence all
constructs in order to identify the correct clones. We there-
fore took a different approach, screening for recombinant
protein expression and cytotoxicity. We screened as many
colonies as possible (more than 90) after ligation (data
not shown) and then transformed these constructed shut-
tle vectors into B. megaterium protoplasts. The resulting
colonies were subjected to screening again by examining
the cytotoxic activity in bacterial crude extracts. The spe-
cific expression of recombinant toxins from the positive
colonies (with cytotoxic activity) was then determined by
western blot. The plasmids encoding tcdA or tcdB respec-
tively were finally subjected to DNA sequencing and no
single mutation was found in either of the toxin genes.
The average yields of recombinant TcdA and TcdB were
about 5 – 10 mg/liter of bacterial culture, which were
much higher than that of native toxins from C. difficile cul-
ture, and up to 20-fold higher than the amount of rTcdA
reported by Burger et al [24]. The fact that we used a dif-
Cytopathic effect of recombinant toxins Figure 3
Cytopathic effect of recombinant toxins. Mouse colonic epithelial CT26 cells in a 96-well plate were untreated (A) or 
treated as following: 10 μl culture supernatant from pHis-TcdB-transformed B. megaterium without (B) or with (C) xylose 
induction; (D) 10 μl culture supernatant from pHis-SP-TcdB-transformed B. megaterium with xylose induction; (E) rTcdB (1 ng/
ml); (F) native TcdB (1 ng/ml); (G) rTcdB (10 ng/ml); (H) native TcdB (10 ng/ml); (I) rTcdA (20 ng/ml); (J) native TcdA (20 ng/
ml); (K) rTcdA (200 ng/ml); (L) native TcdA (200 ng/ml); (M) rTcdA (200 ng/ml) plus 1 μl/well of rabbit anti-TcdA serum; or 
(N) native TcdA (200 ng/ml) plus 1 μl/well of rabbit anti-TcdA serum. Cells were incubated overnight and the morphological 
changes were observed under a phase-contrast microscope.
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Cytotoxic effect of recombinant toxins Figure 4
Cytotoxic effect of recombinant toxins. Mouse colonic epithelial CT26 cells in a 96-well plate were exposed to native () 
or recombinant (Δ) TcdA (A) or exposed to native () or recombinant (Δ) TcdB (B) for 72 hr. The MTT assay was performed 
and cell viability was expressed as the percentage of survival cells without exposure to toxins.
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ferent shuttle vector from that of Burger et al [24] might
explain our higher yields of recombinant proteins. In
addition, we have found out a twelve- to sixteen-hour
period of induction with xylose yielded more recom-
binant proteins than five hours as suggested by the manu-
facturer. The other possible explanation was that the tcdA
gene was fused into orf1 of the vector in the construct
reported by Burger et al [24], resulting a modified N-ter-
minus of recombinant TcdA. This modification might
affect the efficiency of protein expression and/or its stabil-
ity. We inserted the tcdA or tcdB gene into the BsrGI site
and the protein translation directly started from toxin
gene, resulting in recombinant toxins without any N-ter-
minal modification.
To facilitate purification, a His6 tag was fused to the C-ter-
minus of both toxins. One-step of Ni-affinity chromatog-
raphy resulted in approximately 70–80% purity of
recombinant toxins as determined by Coomassie staining
of SDS-PAGE (Figure 1 and data not shown). To achieve a
Glucosylation of Rac1 by recombinant toxins Figure 5
Glucosylation of Rac1 by recombinant toxins. CT26 cells were either untreated or treated with the indicated amount of 
native or recombinant TcdA (A) and TcdB (B) for 5 hr. (C) CT26 cells were pretreated with ammonia chloride for 30 min 
before the exposure of the indicated amount of recombinant toxins for 5 hr. Cells were harvested and western blot was per-
formed as described in the Materials and Methods. Monoclonal antibody clone 102 recognizes unglucosylated Rac1 and has a 
reduced affinity to glucosylated Rac1.
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greater purity, an additional step was introduced after Ni-
affinity chromatography. For rTcdA, thyroglobulin affin-
ity purification was used. rTcdB was further purified by an
anion-exchange fractionation (Figure 1B). These addi-
tional purification steps for rTcdA and rTcdB, respectively,
led to highly pure recombinant toxins. No additional
band was seen on a Coomassie-stained gel (Figure 1B for
rTcdB, and Figure 2A for rTcdA). In addition, there were
no detectable TLR2 or TLR4 stimulants within the purified
recombinant toxins as determined by sensitive bioassays
(unpublished data). This is important because any use of
the impure proteins to study host immune response or
signaling transduction would possibly result in unin-
tended consequences.
Unlike E. coli, a protein secretory pathway is present in B.
megaterium [22,23]. A 28-amino-acid signal peptide of B.
megaterium extracellular esterase LipA can direct the trans-
port of expressed heterologous proteins into medium and
the sequence is removed by a protease after secretion [22].
Because of the nature of exotoxins of native toxins and rel-
atively easy purification from supernatant without the
need for sonication or other means of cell disruptions, we
sought to express rTcdB extracellularly. After inserting the
gene of the leader signaling peptide at the 5' of tcdB, we
were able to generate active secretory rTcdB (Figure 3D)
and Coomassie staining of concentrated supernatant on a
SDS-PAGE gel and western blot showed rTcdB band (Fig-
ure 1D and data not shown). However, for some
unknown reasons, the expression level of rTcdB was sig-
nificantly decreased when the leader sequence was intro-
duced to the construct. In addition, we found the
secretion was very inefficient and the majority of toxins
were still trapped inside of the bacteria, since the total bac-
Disruption of tight junctions by recombinant toxins Figure 6
Disruption of tight junctions by recombinant toxins. HCT-8 cells on transwells were cultured untill the formation of 
tight junctions. The polarized monolayers were untreated (A) or treated with 300 ng/ml of rTcdA for 2 hr (B), 4 hr (C), and 6 
hr (D); or with rTcdB 300 ng/ml for 2 hr (E), and 4 hr (F). Cells on the transwell membrane were fixed and stained with anti-
oocludin and fluorochrome-conjugated secondary antibodies, and then visualized under a confocal microscope.
Medium rTcdA 2 hr rTcdA 4 hr
rTcdA 6 hr rTcdB 2 hr rTcdB 4 hr
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terial lysate contained the majority of toxin activity (data
not shown). This secretory pathway may not be efficient
for such a large size of protein. The low amount of rTcdB
in the medium might also be due to the inefficient refold-
ing after their extracellular transport.
Conclusion
In this study, we have successfully expressed the full-
length of recombinant C. difficile toxin A and B proteins in
B. megaterium and greatly improved the yield of the
recombinant toxins. We were able to obtain 5 – 10 mg of
highly purified rTcdA or rTcdB from one liter of bacterial
culture. These recombinant toxins had similar biological
activities with their native counterparts. We believe the
recombinant toxin proteins will provide an invaluable
tool for studying the pathogenesis of C. difficile associated
disease and host immune response to toxins, as well as
tools for studying the signaling transduction involving
Rho GTPase family proteins.
Methods
Cell lines
Human intestinal epithelial cell lines HCT-8 and mouse
colonic epithelial cell CT26 were purchased from ATCC
(Manassas, VA). All these cells were cultured in DMEM
medium (Invitrogen, Carlsbad, CA) containing 2 mM L-
glutamine, 100 U/ml penicillin G, 50 μg/ml streptomycin
sulfate, and 10% fetal bovine serum.
Purification of native toxins
Native TcdA and TcdB were purified from C. difficile strain
VPI 10463 (kindly provided by Abraham L. Sonenshein,
Tufts University School of Medicine) as described previ-
ously [41]. Briefly, a dialysis bag (100 kDa cutoff, Mill-
pore, Billerica, MA) containing 100 ml of 0.9% NaCl
immersing in a total volume of 1 liter of brain heart infu-
sion (Difco, Lawrence, KS) was inoculated with 5 ml of an
overnight culture of C. difficile, and the culture was grown
in an anaerobic chamber (Bactron BACLITE-1, Sheldon
Manufacturing Inc., Cornelius, OR) at 37°C for 72 hr. The
supernatant collected from the dialysis bag was concen-
trated by ultrafiltration through an Amicon XM-100
membrane (Millipore). The concentrated supernatants
were dialyzed against Tris-HCl (50 mM, pH 7.5) buffer
overnight and loaded onto a HiTrap DEAE column
(Amersham Biosciences, Piscataway, NJ). The fractions
containing toxins were collected and then passed through
a thyroglobulin column, and the flow-through was fur-
ther passed through a Mono Q column (Amersham Bio-
sciences). The elutions from thyroglobulin and mono Q
yielded TcdA and TcdB respectively.
Constructs and cloning
The tcdB gene was amplified from C. difficile (VPI 10463)
chromosomal DNA using forward primer 5'-GCGCTGTA-
CAATGAGTTTAGTTAATAGAAAAC-3' and reverse primer
5'-ATATATGGTACCCTTCACTAATCACTAATTGAGC-3'.
The PCR product was digested by BsrGI and KpnI
enzymes, and then ligated to pHis1522 vector (MoBiTec,
Goettingen, Germany). The full-length of tcdA gene was
amplified using the primers 5'-GCGCTGTACAATGTCTT-
TAATATCTAAAGAAGAGTTAA-3' and 5'-ATATGCAT-
GCCCATA TAT CCCAGGGGCTTTTA-3'. The PCR product
was digested by BsrGI and SphI, and then inserted into
pHis1522 vector. Both sequences of tcdA and tcdB genes in
pHis 1522 vector have been confirmed by DNA sequence
using a panel of primers (Table 1). The gene encoding a
28-amino-acid signal peptide of B. megaterium extracellu-
lar esterase LipA [22] that directs protein secretion in the
secretory pathway of B. megaterium was synthesized by
GeneArt (Regensburg, Germany) and inserted at the site
of BsrGI of the tcdB construct. All restriction endonucle-
ases were purchased from New England Biolabs (Cam-
bridge, MA). All DNA cloning and plasmid construction
were performed at Tufts University and approved by the
Table 1: The sequences of DNA sequencing primers
tcdA Sequencing Primers
Sequence
TcdA-Seq1 Forward CTGCAGCATCTGACATAG
TcdA-Seq2 Forward AAGTTATGAAGCAACATGC
TcdA-Seq3 Forward TCATCTCCATCTATAAGTTCTC
TcdA-Seq4 Forward GTTTCTGGAAATTGTTTGG
TcdA-Seq5 Forward GTTACTGGATGGCAAACC
TcdA-Seq6 Reverse TAGTCCAATAGAGCTAGGTC
TcdA-Seq7 Reverse CCATGTCCAATAAAGGTTAC
TcdA-Seq8 Reverse ACTGCTCCAGTTTCCCAC
TcdA-Seq9 Reverse ACATTTCTACCATTTCCG
TcdA-Seq10 Reverse ATAACCAGTTGAGGCTATG
tcdB Sequencing Primers
Sequence
TcdB-Seq1 Forward GAACAAGAGTTGGTAGAAAG
TcdB-Seq2 Forward TCTTGGTGAAGATGATAATC
TcdB-Seq3 Reverse CCTGGTAACATATCAACATC
TcdB-Seq4 Reverse CTCTCTCTGAACTTCTTGC
TcdB-Seq5 Forward CCTACATTATCTGAAGGATTAC
TcdB-Seq6 Forward GATGTTGATAATGTTGTGAGAG
TcdB-Seq7 Forward ATAGTAAGCCTTCATTTGG
TcdB-Seq8 Reverse GCTGCACCTAAACTTACAC
TcdB-Seq9 Reverse ATTACTTCCATTTACCTCAC
TcdB-Seq10 Forward TTATAGAGGAGCTGTAGAATG
TcdB-Seq11 Reverse GCTTTACCTGTTTCTGGG
Sequencing Primers in pHis-1522 vector
Sequence
phis-seq-F Forward TTTGTTTATCCACCGAACTAAG
phis-seq-R Reverse TGATTGGCTCCAATTCTTGBMC Microbiology 2008, 8:192 http://www.biomedcentral.com/1471-2180/8/192
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Institutional Biosafety Committees and conformed with
NIH Recombinant DNA technology guidelines.
Expression of recombinant toxins
The transformation of Bacillus megaterium protoplasts
were performed according to the manufacturer's instruc-
tion (MoBiTec). The transformed B. megaterium colonies
were picked up and grown overnight in an LB medium
supplemented with 10 μg/ml tetracycline. The overnight
cultures were diluted 1:30 in LB medium containing tetra-
cycline and grown to an optical density (OD600) around
0.3 before the addition of xylose (0.5% w/v) for inducing
protein expression. Bacteria were harvested by centrifuga-
tion after 12 to 16 hr of induction. In case of the secretory
rTcdB, the culture supernatant was also collected.
Purification of recombinant toxins
Purification of recombinant His-tagged rTcdB from bacte-
rial lysate was performed by Ni-affinity chromatography
following an ion-exchange fractionation. Briefly, the B.
megaterium culture pellet (from 100 ml of culture) was
resuspended in 5 ml lysis buffer (300 mM NaCl, 20 mM
imidazole, 20 mM NaH2PO4, 500 μM EDTA, protease
inhibitor cocktail (Cat #P8849, Sigma), adjusted to pH
8.0). Cells were disrupted by sonication and the lysate was
centrifuged at 14,000 g for 20 min. The supernatant was
then passed through a nickel-charged HiTrap chelating
HP column (Amersham Biosciences, Piscataway, NJ) and
the bound His-tagged rTcdB was eluted with an elution
buffer containing 250 mM imidazole, 300 mM NaCl, and
20 mM NaH2PO4, pH 8.0. The eluent was then desalted
and applied to HiTrap Q column (Amersham Bio-
sciences) and rTcdB was eluted by a gradient concentra-
tion of NaCl solution. The fraction containing rTcdB was
combined and stored at -80°C until use. To purify rTcdB
from supernatant, the bacterial supernatant was passed
through a 0.45 mm filter first, and then concentrated
through ultrafiltration with a 100 kDa cutoff membrane
(Millipore). The concentrated supernatant was then per-
formed with Ni-affinity chromatography following an
ion-exchange fractionation as described above. rTcdA was
purified by Ni-affinity chromatography following an thy-
roglobulin affinity column. The method for thyroglobulin
purification has been described elsewhere [16].
SDS-PAGE and western blot
CT26 cells were exposed to toxins for 5 hr before they were
harvested. In other experiments, ammonium chloride was
pre-incubated with the cells for 30 min before the cells
were exposed to toxins. The methods for SDS-PAGE and
western blot have been described previously [42,43].
Briefly, the samples were boiled for 5 min in 1× NuPage
SDS sample buffer (Invitrogen) and then loaded on a gra-
dient (4 – 20%) sodium dodecyl sulfate-polyacrylamide
gel (SDS-PAGE) (BioRad, Hercules, CA). After electro-
phoresis, the gels were stained with GelCode Blue (Pierce,
Rockford, IL) according to the manufacturer's instruc-
tions. For western blot, TcdB-specific monoclonal anti-
body (clone 5A8-E11, Meridian Life Science, Inc.,
Memphis, TN), and TcdA-specific monoclonal antibodies
(clone PCG4.1, Meridian Life Science, Inc.; or clone A1E6
generated in our laboratory) and HRP-conjugated anti-
mouse IgG (Amersham Biochiences) were used as the pri-
mary and secondary antibodies respectively and the pro-
tein bands were visualized by an enhanced
chemiluminescence assay (ECL, Amersham Biochiences).
To determine Rac1 glucosylation, the antibody (clone
102, BD Biosciences, San Diego, CA) specific against non-
glucosylated form of Rac1 was used. Anti-actin antibody
(clone AC-40, Sigma, St. Louis, MO) was used to monitor
an equal loading of samples.
Cytotoxicity assay
Subconfluent CT26 cells (2 ×104/well) seeded in 96-well
plates were incubated with toxins, bacterial culture super-
natants, or crude extracts. For blocking experiments, 1 μl/
well of rabbit anti-serum against TcdA was added simulta-
neously with toxins. Cells were cultured overnight and the
morphological changes of CT26 cells were observed by
light microscopy with a CCD camera. For the MTT assay,
after 3 days of incubation, 10 μL of MTT (5 mg/ml) were
added to each well and the plate was further incubated at
37°C for 2 h. The formazan was solubilized with acidic
isopropanol (0.4 N HCl in absolute isopropanol), and
absorbance at 570 nm was measured using a 96-well
ELISA reader. Cell viability was expressed as the percent-
age of survival of the control wells.
Disruption of tight junctions by recombinant toxins
HCT-8 cells were seeded into a 24-well plate with 3-μm
pore transwells (Corning Inc., Wilkes Barre, PA) and cul-
tured for 10 to 14 days. Transepithelial resistance (TER)
was monitored daily until TER reached 1000 Ω/cm2.
rTcdA (300 ng/ml) or rTcdB (300 ng/ml) was added into
the upper chamber of transwells for the indicated time.
The cells were fixed and stained with anti-occludin (clone
OC-3F10, Invitrogen) and fluorochrome-conjugate sec-
ondary antibodies. The slides were examined under con-
focal microscope (Leica LSM TSC SP2 AOBS).
Authors' contributions
GY and BZ carried out the molecular cloning, design of
constructs, DNA sequencing, and data preparation. JW
carried out protein purification. XH established the meth-
ods for protein purification. XS and WN participated in
molecular cloning. ST contributed intellectually to exper-
imental design and text. HP initiated the project, con-
ceived the whole study and experimental design, and
drafted the manuscript. All authors read and approved the
final manuscript.BMC Microbiology 2008, 8:192 http://www.biomedcentral.com/1471-2180/8/192
Page 12 of 13
(page number not for citation purposes)
Acknowledgements
The authors thank Dr. Abraham L. Sonenshein for a critical review of the 
manuscript. This work was supported by NIH N01AI30050, and in part by 
NIH K01DK076549 to HF and National High Technology Development 
Program of China (2007AA021702) to JW.
References
1. Cloud J, Kelly CP: Update on Clostridium difficile associated
disease.  Curr Opin Gastroenterol 2007, 23(1):4-9.
2. Owens JR, Donskey C, Gaynes R, Loo V, Muto C: Antimicrobial-
Associated Risk Factors for Clostridium difficile Infection.
Clinical Infectious Diseases 2008, 46(s1):S19-S31.
3. Kuijper EJ, van Dissel JT, Wilcox MH: Clostridium difficile: chang-
ing epidemiology and new treatment options.  Curr Opin Infect
Dis 2007, 20(4):376-383.
4. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV,
Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-var-
iant strain of Clostridium difficile.  N Engl J Med 2005,
353(23):2433-2441.
5. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S,
Bourgault AM, Nguyen T, Frenette C, Kelly M, et al.: A predomi-
nantly clonal multi-institutional outbreak of Clostridium dif-
ficile-associated diarrhea with high morbidity and mortality.
N Engl J Med 2005, 353(23):2442-2449.
6. Kelly CP, Pothoulakis C, LaMont JT: Clostridium difficile colitis.
N Engl J Med 1994, 330(4):257-262.
7. Voth DE, Ballard JD: Clostridium difficile toxins: mechanism of
action and role in disease.  Clin Microbiol Rev 2005, 18(2):247-263.
8. Just I, Gerhard R: Large clostridial cytotoxins.  Reviews of physiol-
ogy, biochemistry and pharmacology 2004, 152:23-47.
9. Schirmer J, Aktories K: Large clostridial cytotoxins: cellular
biology of Rho/Ras-glucosylating toxins.  Biochimica et biophysica
acta 2004, 1673(1–2):66-74.
10. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard
E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, et al.: GT160-
246, a toxin binding polymer for treatment of Clostridium
difficile colitis.  Antimicrobial agents and chemotherapy 2001,
45(8):2340-2347.
11. Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD: Biological
activities of toxins A and B of Clostridium difficile.  Infect
Immun 1982, 35(3):1147-1150.
12. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD: Effects of
Clostridium difficile toxins given intragastrically to animals.
Infect Immun 1985, 47(2):349-352.
13. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis
C: Clostridium difficile toxin B is an inflammatory entero-
toxin in human intestine.  Gastroenterology 2003, 125(2):413-420.
14. Shin BM, Kuak EY, Yoo SJ, Shin WC, Yoo HM: Emerging toxin A-
B+ variant strain of Clostridium difficile responsible for pseu-
domembranous colitis at a tertiary care hospital in Korea.
Diagn Microbiol Infect Dis 2007.
15. Kikkawa H, Hitomi S, Watanabe M: Prevalence of toxin A-non-
producing/toxin-B-producing Clostridium difficile in the Tsu-
kuba-Tsuchiura district, Japan.  J Infect Chemother 2007,
13(1):35-38.
16. Krivan HC, Wilkins TD: Purification of Clostridium difficile
toxin A by affinity chromatography on immobilized thy-
roglobulin.  Infect Immun 1987, 55(8):1873-1877.
17. Sullivan NM, Pellett S, Wilkins TD: Purification and characteriza-
tion of toxins A and B of Clostridium difficile.  Infect Immun
1982, 35(3):1032-1040.
18. Keel MK, Songer JG: The distribution and density of Clostrid-
ium difficile toxin receptors on the intestinal mucosa of neo-
natal pigs.  Veterinary pathology 2007, 44(6):814-822.
19. Phelps CJ, Lyerly DL, Johnson JL, Wilkins TD: Construction and
expression of the complete Clostridium difficile toxin A gene
in Escherichia coli.  Infection and immunity 1991, 59(1):150-153.
20. Tang-Feldman YJ, Ackermann G, Henderson JP, Silva J Jr, Cohen SH:
One-step cloning and expression of Clostridium difficile
toxin B gene (tcdB).  Molecular and cellular probes 2002,
16(3):179-183.
21. Wren BW, Clayton CL, Mullany PP, Tabaqchali S: Molecular clon-
ing and expression of Clostridium difficile toxin A in
Escherichia coli K12.  FEBS letters 1987, 225(1–2):82-86.
22. Malten M, Biedendieck R, Gamer M, Drews AC, Stammen S, Buchholz
K, Dijkhuizen L, Jahn D: A Bacillus megaterium plasmid system
for the production, export, and one-step purification of affin-
ity-tagged heterologous levansucrase from growth medium.
Applied and environmental microbiology 2006, 72(2):1677-1679.
23. Vary PS, Biedendieck R, Fuerch T, Meinhardt F, Rohde M, Deckwer
WD, Jahn D: Bacillus megaterium–from simple soil bacterium
to industrial protein production host.  Applied microbiology and
biotechnology 2007, 76(5):957-967.
24. Burger S, Tatge H, Hofmann F, Genth H, Just I, Gerhard R: Expres-
sion of recombinant Clostridium difficile toxin A using the
Bacillus megaterium system.  Biochem Biophys Res Commun 2003,
307(3):584-588.
25. Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, Guerrant RL:
Mechanism of Clostridium difficile toxin A-induced apopto-
sis in T84 cells.  J Infect Dis 2002, 186(10):1438-1447.
26. Matarrese P, Falzano L, Fabbri A, Gambardella L, Frank C, Geny B,
Popoff MR, Malorni W, Fiorentini C: Clostridium difficile toxin B
causes apoptosis in epithelial cells by thrilling mitochondria:
involvement of ATP-sensitive mitochondrial potassium
channels.  J Biol Chem 2007.
27. Kim H, Kokkotou E, Na X, Rhee SH, Moyer MP, Pothoulakis C, Lam-
ont JT: Clostridium difficile toxin A-induced colonocyte apop-
tosis involves p53-dependent p21(WAF1/CIP1) induction via
p38 mitogen-activated protein kinase.  Gastroenterology 2005,
129(6):1875-1888.
28. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K:
Glucosylation of Rho proteins by Clostridium difficile toxin
B.  Nature 1995, 375(6531):500-503.
29. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, Akto-
ries K: The enterotoxin from Clostridium difficile (ToxA)
monoglucosylates the Rho proteins.  J Biol Chem 1995,
270(23):13932-13936.
30. Genth H, Huelsenbeck J, Hartmann B, Hofmann F, Just I, Gerhard R:
Cellular stability of Rho-GTPases glucosylated by Clostrid-
ium difficile toxin B.  FEBS letters 2006, 580(14):3565-3569.
31. Na X, Kim H, Moyer MP, Pothoulakis C, LaMont JT: gp96 is a
human colonocyte plasma membrane binding protein for
Clostridium difficile toxin A.  Infect Immun 2008,
76(7):2862-2871.
32. Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti
Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, et al.: Rabbit
sucrase-isomaltase contains a functional intestinal receptor
for Clostridium difficile toxin A.  J Clin Invest 1996,
98(3):641-649.
33. Krivan HC, Clark GF, Smith DF, Wilkins TD: Cell surface binding
site for Clostridium difficile enterotoxin: evidence for a gly-
coconjugate containing the sequence Gal alpha 1-3Gal beta
1-4GlcNAc.  Infect Immun 1986, 53(3):573-581.
34. Henriques B, Florin I, Thelestam M: Cellular internalisation of
Clostridium difficile toxin A.  Microbial pathogenesis 1987,
2(6):455-463.
35. Jefferson KK, Smith MF Jr, Bobak DA: Roles of intracellular cal-
cium and NF-kappa B in the Clostridium difficile toxin A-
induced up-regulation and secretion of IL-8 from human
monocytes.  J Immunol 1999, 163(10):5183-5191.
36. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL,
Parkos CA: Clostridium difficile toxins disrupt epithelial bar-
rier function by altering membrane microdomain localiza-
tion of tight junction proteins.  Infect Immun 2001,
69(3):1329-1336.
37. Reineke J, Tenzer S, Rupnik M, Koschinski A, Hasselmayer O, Schrat-
tenholz A, Schild H, von Eichel-Streiber C: Autocatalytic cleavage
of Clostridium difficile toxin B.  Nature 2007,
446(7134):415-419.
38. Egerer M, Giesemann T, Jank T, Satchell KJ, Aktories K: Auto-cata-
lytic cleavage of Clostridium difficile toxins A and B depends
on cysteine protease activity.  The Journal of biological chemistry
2007, 282(35):25314-25321.
39. Makoff AJ, Oxer MD, Romanos MA, Fairweather NF, Ballantine S:
Expression of tetanus toxin fragment C in E. coli: high level
expression by removing rare codons.  Nucleic acids research
1989, 17(24):10191-10202.
40. Makoff AJ, Ballantine S, Smallwood AE, Neil F: Expression of teta-
nus toxin fragment C in E. coli: its purification and potential
use as a vaccine.  Biotechnology 1989, 7:1043-1046.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Microbiology 2008, 8:192 http://www.biomedcentral.com/1471-2180/8/192
Page 13 of 13
(page number not for citation purposes)
41. Gerhard R, Burger S, Tatge H, Genth H, Just I, Hofmann F: Compar-
ison of wild type with recombinant Clostridium difficile toxin
A.  Microb Pathog 2005, 38(2–3):77-83.
42. Feng H, Zeng Y, Whitesell L, Katsanis E: Stressed apoptotic tumor
cells express heat shock proteins and elicit tumor-specific
immunity.  Blood 2001, 97(11):3505-3512.
43. Feng H, Zhang D, Palliser D, Zhu P, Cai S, Schlesinger A, Maliszewski
L, Lieberman J: Listeria-infected myeloid dendritic cells pro-
duce IFN-beta, priming T cell activation.  J Immunol 2005,
175(1):421-432.